Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations.
about
Ganoderma lucidum inhibits proliferation of human ovarian cancer cells by suppressing VEGF expression and up-regulating the expression of connexin 43Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometryProteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening"OMIC" tumor markers for breast cancer: A reviewFrom genomes to societies: a holistic view of determinants of human healthIssues in solid-organ transplantation in children: translational research from bench to bedside.Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advicesSerum amyloid A: an acute-phase protein involved in tumour pathogenesisIdentification of novel molecular targets for endometrial cancer using a drill-down LC-MS/MS approach with iTRAQSerum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assaysProteomics and mass spectrometry for cancer biomarker discoveryScreening for potential serum-based proteomic biomarkers for human type 2 diabetes mellitus using MALDI-TOF MS.A simulation-approximation approach to sample size planning for high-dimensional classification studies.Application of machine learning to proteomics data: classification and biomarker identification in postgenomics biology.Ovarian cancer identification based on dimensionality reduction for high-throughput mass spectrometry data.Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).Data pre-processing in liquid chromatography-mass spectrometry-based proteomics.Preprocessing and Analysis of LC-MS-Based Proteomic DataEarly diagnostic protein biomarkers for breast cancer: how far have we come?Changes in liver mitochondrial plasticity induced by brain tumor.Diagnosis of gastric cancer using decision tree classification of mass spectral data.Topic model-based mass spectrometric data analysis in cancer biomarker discovery studiesAccounting for isotopic clustering in Fourier transform mass spectrometry data analysis for clinical diagnostic studies.Advances in coupling microfluidic chips to mass spectrometry.Whole-cell MALDI-TOF mass spectrometry is an accurate and rapid method to analyze different modes of macrophage activation.Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers.Proteomics and the analysis of proteomic data: an overview of current protein-profiling technologiesClassification of premalignant pancreatic cancer mass-spectrometry data using decision tree ensembles.High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry.Proteomics for biodefense applications: progress and opportunities.MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer.Correcting common errors in identifying cancer-specific serum peptide signaturesDifferential exoprotease activities confer tumor-specific serum peptidome patternsProteomics: a paradigm shift.Clinical proteomics and mass spectrometry profiling for cancer detection.Contributions of advanced proteomics technologies to cancer diagnosis.Preclinical and post-treatment changes in the HCC-associated serum proteome.Shotgun glycopeptide capture approach coupled with mass spectrometry for comprehensive glycoproteomics.Link test--A statistical method for finding prostate cancer biomarkers.LIMPIC: a computational method for the separation of protein MALDI-TOF-MS signals from noise.
P2860
Q21254678-57B795CF-9718-4DD7-8BA7-1FE1ADE4D7D3Q24684774-A94F0540-00A6-489E-862C-BC6CFEB7B525Q24685774-82B87301-81FA-48DD-AF46-0B162FBA269BQ26773092-B22B64C3-A729-4C2F-BB73-7586CF61EA04Q26827143-12DE5977-D1A3-4C97-9659-695996C0A3D1Q27023312-BA953816-2E0A-4C05-BBEB-2C7954713A62Q28287384-C03F9DFB-EA46-488F-8C65-0ADF96AAD636Q28291806-88F4AF8C-2456-4AFA-B361-5BC1DCE5866EQ28743151-9EDF9029-ADCD-4EBA-8ECD-19B2F1C7CE10Q28743469-FBAC3007-B69D-4241-863B-598D4190A9ACQ28766969-2DFA8247-8559-48C6-98DF-BE1990C3F3F7Q30395380-40D7E9D6-64C4-4978-B19F-95C36C8DC595Q30488260-BCCCAF4A-A846-4203-964E-C74C8A194DA5Q30676067-C41A3ED2-8D57-4012-92B7-4FD6AA816BB8Q30985505-4A6386DE-1E31-43D2-996E-A5BA51FB4605Q30987570-9EFBE062-349D-4BDA-904B-3027CBC128A6Q31003899-93D18215-DE0F-42D8-98A7-697FE1C5E39BQ31013864-A817D31B-34F4-49D4-AD73-9D2BE7A6296EQ31043570-B7238DE9-C158-4F5F-889E-03FF3E0E4635Q31064163-2B1C9B81-6FCF-4694-A687-3FE282189ECFQ31068299-57E4ED9C-BE9B-4FB2-ADFC-CC9982EE9160Q31122171-92148735-CC21-4EAB-A272-315556931D5DQ31133682-0552E7CE-CCC0-4AC1-B134-F779AE1E235AQ31147615-D0DBD48E-5BCB-4D41-9DF7-1A2E9BF02EE7Q31148237-29FD32DC-C27B-4405-89B6-1E6D85C82505Q31148835-9F3B55BF-FC08-4779-8BAD-912C8C9B827AQ31153300-03CB6701-C3EB-4CFE-A829-6CDA48117A99Q31158913-BB141442-084E-4AD2-BC59-F136057289FEQ33210158-5BE9CA65-2FCD-4983-A765-D8D847C1377CQ33215043-1C9C0ABD-D74E-4BC8-8C15-121E725DF619Q33217610-6C95E460-CFD6-4511-BB30-623C6BE214B2Q33221189-218DFAB8-54EE-4EBF-B98F-E203BD176D61Q33230965-1D9E1CB1-4995-4AC9-B34E-F5B703A189ADQ33231862-547EAA7F-50EA-4FD4-A27B-E5C652295465Q33246668-107AA13C-0769-46C6-BF58-36B72C71935EQ33256357-9854BDA7-EF36-4E11-99C7-063FD296ABE9Q33261336-A6737A4B-B231-4563-B2E6-7046881B3A16Q33262142-2B95933B-CBC6-4152-9431-5F466C0415D4Q33264623-D5CB4AFB-554F-4A6A-9AF6-D6A03E73810DQ33280025-28FC0F57-DD00-489E-AF93-2615CEFA9AFF
P2860
Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Mass spectrometry as a diagnos ...... ies and potential limitations.
@ast
Mass spectrometry as a diagnos ...... ies and potential limitations.
@en
type
label
Mass spectrometry as a diagnos ...... ies and potential limitations.
@ast
Mass spectrometry as a diagnos ...... ies and potential limitations.
@en
prefLabel
Mass spectrometry as a diagnos ...... ies and potential limitations.
@ast
Mass spectrometry as a diagnos ...... ies and potential limitations.
@en
P2860
P1476
Mass spectrometry as a diagnos ...... ies and potential limitations.
@en
P2860
P304
P356
10.1074/MCP.R400007-MCP200
P577
2004-02-28T00:00:00Z